AbbVie Inc. (BCBA:ABBV)

Market Cap	375.32T
Revenue (ttm)	61.56T
Net Income (ttm)	4.46T
Shares Out	n/a
EPS (ttm)	2,510.97
PE Ratio	84.18
Forward PE	14.55
Dividend	417.13 (1.91%)
Ex-Dividend Date	Apr 15, 2025

Volume	1,002
Average Volume	2,145
Open	21,825
Previous Close	21,900
Day's Range	21,575 - 21,850
52-Week Range	18,325 - 27,925
Beta	n/a
RSI	43.76
Earnings Date	Jul 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD